- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HCW Biologics stellt neue Daten zur Krebstherapie auf der SITC-Tagung vor | 3 | Investing.com Deutsch | ||
| Fr | HCW Biologics presents cancer therapy data at SITC meeting | 1 | Investing.com | ||
| Fr | HCW Biologics Inc.: HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer | 3 | GlobeNewswire (USA) | ||
| Fr | HCW Biologics Inc.: HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society ... | 1 | GlobeNewswire (USA) | ||
| Do | HCW Biologics secures up to $10M debt financing for phase 1 study | 1 | Investing.com | ||
| Do | HCW Biologics sichert sich Fremdfinanzierung von bis zu 10 Mio. $ für Phase-1-Studie | - | Investing.com Deutsch | ||
| Do | HCW Biologics Inc.: HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing | 3 | GlobeNewswire (USA) | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Do | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.10. | HCW Biologics erhält FDA-Richtlinien für klinische Studie zu Krebsmedikament | 1 | Investing.com Deutsch | ||
| 02.10. | HCW Biologics Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.09. | HCW Biologics prices $1.5M private placement offering | 2 | Investing.com | ||
| 24.09. | HCW Biologics kündigt Privatplatzierung über 1,5 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 24.09. | HCW Biologics Inc.: HCW Biologics Announces Pricing of $1.5 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 11.09. | Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AstraZeneca, GPCR Lead Clinical Trials | 1.831 | AFX News | NEW BRUNSWICK (dpa-AFX) - Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.Notable... ► Artikel lesen | |
| 08.09. | HCW Biologics schließt Vertriebsvereinbarung mit Akron Biotech | 3 | Investing.com Deutsch | ||
| 08.09. | HCW Biologics signs distribution deal with Akron Biotech | 3 | Investing.com | ||
| 08.09. | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.09. | HCW Biologics Inc.: HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells | 3 | GlobeNewswire (USA) | ||
| 02.09. | HCW Biologics Inc.: HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment | 1 | GlobeNewswire (USA) | ||
| 28.08. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 5 | SEC Filings |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 1,270 | +1,60 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,144 | -0,69 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| CEL-SCI | 1,180 | +3,51 % | CEL-SCI Corporation: CEL-SCI Presents New Phase 3 Multikine Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival | Target Population Selection: Biomarker profile applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS 10%) or zero... ► Artikel lesen | |
| MOLECULIN BIOTECH | 7,579 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting | ||
| PDS BIOTECHNOLOGY | 1,125 | +2,27 % | PDS Biotechnology Corporation: PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors | Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation... ► Artikel lesen | |
| LISATA THERAPEUTICS | 0,835 | +0,60 % | Lisata Therapeutics, Inc.: Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly | Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks... ► Artikel lesen | |
| GEOVAX LABS | 0,158 | +0,06 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| COCRYSTAL | 0,865 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| GOSSAMER BIO | 8,666 | -2,23 % | XFRA 4GB0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DECOY THERAPEUTICS | 1,130 | 0,00 % | Decoy Therapeutics plant Einreichung für Coronavirus-Wirkstoff im zweiten Halbjahr 2027 | ||
| JASPER THERAPEUTICS | 16,750 | -0,65 % | Jasper Therapeutics to execute 1-for-30 reverse stock split | ||
| CHEMOMAB THERAPEUTICS | 1,290 | -2,27 % | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | ||
| VISTAGEN THERAPEUTICS | 0,165 | +0,73 % | Vistagen Therapeutics, Inc.: Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder | Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on "Publications" section of Company's website SOUTH SAN FRANCISCO, Calif., Sept.... ► Artikel lesen | |
| IN8BIO | 0,735 | -9,82 % | IN8bio, Inc: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| METAVIA | 1,410 | -1,40 % | MetaVia Inc.: MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data | DA-1726 Also Demonstrated Statistically Significant 13.5% Placebo-Adjusted Weight Loss and Reduced Mean HbA1c from 5.79% to 5.33% in Participants Without DiabetesNo New Gastrointestinal Adverse Events... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,98 %) liegt der Kurs bei 1,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.